Harmony Biosciences Holdings, Inc. (HRMY) earnings date
Feb 23, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | before open | 35 | 8-K |
| Q2 FY2026 | Tue, Aug 4, 2026 | before open | 35 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | before open | 37 | 8-K |
| Q4 FY2025 | Tue, Feb 24, 2026 | before open | 55 | 8-K |
| Q3 FY2025 | Tue, Nov 4, 2025 | before open | 35 | 8-K |
| Q2 FY2025 | Tue, Aug 5, 2025 | before open | 36 | 8-K |
| Q1 FY2025 | Tue, May 6, 2025 | before open | 36 | 8-K |
| Q4 FY2024 | Tue, Feb 25, 2025 | before open | 56 | 8-K |
What they guided beta
| Q3 FY2026 | " Exhibit 99.1 Harmony Biosciences Reports Q3 Financial Results On Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B Repeated Once-Daily Dosing with BP-205 in Multiple-Ascending Dose Study Reinforces Favorable Safety, Tolerability and Pharmacokinetic Profile Observed in Single-Ascending Dose Study Result" exhibit |
| Q3 FY2026 | "WAKIX® (pitolisant) delivered third quarter net revenue of $269 million, driven by strong demand of 400 net patient adds, and the Company remains on track to achieve full-year WAKIX net revenue guidance of $1.0 billion to $1.04 billion. The encouraging preliminary results from the MAD study with BP-205, following 14 days of repeated once-daily dosing, reinforce the favorable safety, tolerability and pharmacokinetic profile observed in the single-ascending dose (SAD) portion of the study." exhibit |
| Q3 FY2026 | "Harmony remains on track to report Phase 1b data in sleep-deprived healthy volunteers in the first quarter of 2027, followed by the initiation of Phase 2 studies across multiple CNS indications by mid-2027. Additionally, as announced on October 12, 2026, Peter Anastasiou, Senior Executive Vice President and Chief Operating Officer, will become President and Chief Executive Officer effective January 1, 2027, succeeding Jeffrey Dayno, MD, who will retire on December 31, 2026." exhibit |
| Q3 FY2026 | "Significant market opportunity remains: approximately 170,000 people in the U.S. are living with narcolepsy, fewer than 50% are diagnosed, and brand penetration is approximately 20% On Track to Achieve 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion Advance Robust, Self-Funded Pipeline BP-205 (Orexin-2 receptor agonist) BP-205 MAD Study Design and Preliminary Results" exhibit |
| Q3 FY2026 | "Next steps in BP-205 development: o Phase 1b study in sleep-deprived healthy volunteers initiated in Q3 in the US; data expected in Q1 2027 o Expect to initiate Phase 2 studies to evaluate multiple CNS indications by mid-2027 " exhibit |
| Q2 FY2026 | " Exhibit 99.1 Harmony Biosciences Announces Record Q2 2026 Re venue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1. 0 Billion to $1.04 Billion Phase 1 SAD Data for BP-205 Demonstrate Favorable PK and Safety/Tolerability Profiles ; Phase 1 MAD Data Expected in Q4 2026 BP-205 IND Open in US; Initiating Phase 1b Study in Sleep-Deprived Healthy Volunt" exhibit |
| Q2 FY2026 | "WAKIX remains on track to achieve full-year net revenue guidance of $1.0 billion to $1.04 billion. The Company also announced encouraging single ascending dose (SAD) data from its Phase 1 study of BP-205, demonstrating favorable pharmacokinetic (PK) and safety/tolerability profiles that reinforce Harmony’s conviction in BP-205 as a potential best-in-class orexin-2 receptor (OX2R) agonist." exhibit |
| Q2 FY2026 | "These data support Harmony’s robust orexin development strategy, including initiating Phase 2 studies beginning in mid-2027 to evaluate multiple CNS indications. “Our record second-quarter revenue reflects sustained demand for WAKIX and keeps us firmly on track to deliver over $1 billion in revenue this year." exhibit |
| Q2 FY2026 | "Net product revenue for the quarter ended June 30, 2026, was $261.3 million, representing 30% growth vs 2Q25 o Estimated average number of patients grew 450 to 8,950 in Q2, which is the 2 nd highest average patient growth ever o Executed expansion of field sales, remote sales, field reimbursement and patient outreach teams with all roles hired, trained and fully deployed in 2Q o Launched online portal and changes to reimbursement support process to enable patients to secure WAKIX faster and with higher success rate On Track to Achieve 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 " exhibit |
| Q2 FY2026 | "Next steps in BP-205 development o Multiple ascending dose (MAD) data in healthy volunteers expected in Q4 o US IND open; initiate Phase 1b study in sleep-deprived healthy volunteers in Q3; data expected in early 2027 " exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/HRMY
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/HRMY
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/HRMY/"><img src="https://veritasdata.dev/embed/HRMY.svg" alt="HRMY earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/HRMY/)
Script
<script async src="https://veritasdata.dev/embed/HRMY.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/HRMY"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.